于稳定价格期内按每股H股介乎5.79港元至11.66港元的价格接连于市场购入合共386.68万股H股，约占全球发售可供认购发售股份总数(经计及发售量调整权获悉数行使后但于任何超额配股权获行使前)的15.00%，以促进该等H股将交付予已同意延迟交付彼于全球发售项下认购的386.68万股H股的承配人。于稳定价格期内，稳定价格操作人、其联属人士或其任何一致行动人士于2024年11月1日(星期五)按每股H股6.06港元的价格于市场最后一次购入股份。Hemco Medical Technology (02576) has announced that the stabilisation period for the global offering will end on November 2, 2024.
According to the Financial Intelligence APP, Hemco Medical Technology (02576) has announced that the stabilisation period for the global offering has ended on November 2, 2024 (Saturday) (i.e. 30 days after the deadline for submitting applications for public offering in Hong Kong).
The stabilising manager Morgan Stanley Asia Limited and its affiliates or any person acting in concert acquired a total of 3.8668 million H shares during the stabilisation period, accounting for approximately 15.00% of the total number of shares available for subscription and sale in the global offering (after exercising the over-allotment option but before any exercise of the over-allotment option).
During the stabilisation period, purchases of a total of 3.8668 million H shares were made at a price ranging from HK$5.79 to HK$11.66 per H share to facilitate the delivery of these H shares to the underwriters who have agreed to delay the receipt of the 3.8668 million H shares subscribed under the global offering. During the stabilisation period, the stabilising manager, its affiliates or any person acting in concert made the final purchases at a price of HK$6.06 per H share on November 1, 2024 (Friday).
The overall coordinator (on its own behalf and on behalf of the international underwriters) did not exercise the over-allotment option during the stabilisation period, and the over-allotment option expired on November 2, 2024 (Saturday). Therefore, there is no issuance or planned issuance of H shares under the over-allotment option.
